source
- FDA imposes partial clinical hold on Biohaven's experimental epilepsy drug BHV-7000FDA announced a partial clinical hold on Biohaven's ion channel program, affecting the epilepsy trial of the experimental drug BHV-7000. The hold was issued after the agency requested additional p…
- Reverse mergers surge as biotech firms seek public listings via shell companiesReverse mergers, once dismissed, are now a common route for biotech startups to gain a public listing by merging with shell companies. Data from JB Strategy Partners shows roughly two dozen such d…